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ABSTRACT 
 
Amyloid fibrils formed by a variety of peptides are biological markers of different 
human diseases, such as Alzheimer, Parkinson or Type II diabetes, and are structural 
constituents of bacterial biofilms. Novel fluorescent probes offering improved 
sensitivity or specificity towards that diversity of amyloid fibrils, or providing 
alternative spectral windows are needed to improve the detection or the identification of 
amyloid structures. One potential source for such new probes is offered by molecules 
known to interact with fibrils, such as the inhibitors of amyloid aggregation found in 
drug discovery projects. Here, we show the feasibility of the approach by designing, 
synthesizing and testing several pyrene-based fluorescent derivatives of a previously 
discovered inhibitor of the aggregation of the Aβ1-42 peptide. All the derivatives tested 
retain the interaction with the amyloid architecture and allow its staining. The more 
soluble derivative, compound 1D, stains similarly well amyloid fibrils formed by Aβ1-42, 
α-synuclein or amylin, provides a sensitivity only slightly lower than that of Thioflavin 
T, displays a large Stokes shift, allows an efficient excitation in the UV spectral region, 
and it is not cytotoxic. Compound 1D can also stain amyloid fibrils formed by 
Staphylococcal peptides present in biofilm matrices and can be used to distinguish, by 
direct staining, S. aureus biofilms containing amyloid forming phenol soluble modulins 
from those lacking them. 
 
Keywords: amyloid fibrils, aggregation inhibitor, pyrene, Stokes shift, fluorescent 
probes, biofilm matrix 
 
GRAPHICAL ABSTRACT 
 
 
 
  
4 
 
INTRODUCTION 
 
More than 46 million people are affected by Alzheimer’s disease (AD) [1–3], a 
neurodegenerative disorder that, since its discovery in 1906 [4], has become the major 
cause of dementia in humans. Because getting older is the main risk factor for the 
development of AD [5–7] and average life expectancy keeps rising, there is a need to 
develop effective therapeutic drugs and diagnostic tools targeting the main biomarkers 
of the disease. The two classic lesions that characterize AD are senile plaques made of 
extracellular fibrillar deposits of amyloid beta peptide (Aβ) aggregates, and 
intraneuronal neurofibrillary tangles composed of hyperphosphorylated tau protein [8]. 
The main components of amyloid plaques are two N-terminal β-amyloid precursor 
protein (APP) fragments [9–11]: Aβ1-40 and Aβ1-42, the latter having the greatest 
aggregating activity due to its lower solubility.  
According to the amyloid cascade hypothesis, aggregation of Aβ peptide triggers the 
development of AD [12]. Blocking the Aβ production/aggregation cascade seems a 
promising strategy to develop drugs for AD treatment [13]. By adapting high 
throughput experimental screening methods previously used to discover 
pharmacological chaperones [14] and protein inhibitors [15], we reported the discovery 
of four compounds that inhibit the aggregation of Aβ17-40 and Aβ1-42 both in vitro and in 
fungi models [16]. As those compounds interact with Aβ aggregating species [17] 
suitable fluorescent derivatives could be used to detect and quantitate Aβ fibrils by 
means of fluorescence microscopy. Thioflavin T (ThT) is at present the fluorescent 
probe most commonly used to stain amyloid fibrils and to follow the aggregation 
kinetics of amyloidogenic proteins [18]. ThT recognizes the generic amyloid motif and 
interacts with the fibrils formed by diverse, unrelated proteins [19]. New fluorescent 
probes with increased sensitivity or selectivity, or that allow broadening the working 
spectroscopic window could help improve the detection or the identification of amyloid 
structures.  
In amyloidogenic diseases, amyloid fibril formation occurs upon aberrant misfolding of 
soluble, functional proteins. However, amyloid fibrils are not always the result of 
aberrant protein folding, and some are produced on purpose under non-pathological 
conditions. Thus, the microbial world makes use of this type of protein fibrils for a 
number of processes, such as adhesion to host tissues [20] and the building of structural 
scaffolds in biofilm matrices [21]. One of the first examples of amyloid systems related 
to biofilm matrix formation was described in Staphylococcus aureus. Functional fibrils 
with amyloidogenic properties formed by the polymerization of small peptides known 
as phenol-soluble modulins (PSMs) increase the stability of S. aureus biofilms [22]. A 
fluorescent chemical compound that could stain amyloid-like structures would be useful 
to detect the amyloid nature of the bacterial biofilm matrix formed by pathogenic 
bacteria. 
Our aim is to develop new fluorescent markers for the detection of Aβ and other 
amyloid fibrils by attaching a high quantum yield fluorescent dye to an organic 
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molecular scaffold that has been previously demonstrated to interact with Aβ 
aggregates. Herein, we report the design, synthesis, and in vitro testing of several 
fluorescent derivatives of compound 1 (Chart 1). One of them, compound 1D, stains 
Aβ, amylin and α-synuclein fibrils and is shown to specifically label PSMs 
amyloidogenic fibrils in the S. aureus biofilm matrix.  
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Chart 1. Chemical structures of Compound 1 and its fluorescent derivatives 
 
 
 
MATERIALS AND METHODS 
 
Chemicals, peptides and proteins  
All chemicals for synthesis were obtained from commercial suppliers and were used 
without further purification. Aβ17-40 and Ac-amylin 8-37 were purchased from 
GeneCust, Aβ1-42 from GenicBio, and α-PSM1 and α-PSM4 from ChinaPeptides. 
Alpha-synuclein fibrils (171 µM in PBS buffer) were a generous gift from Dr. NC. A 
Aβ17-40 stock solution (418 µM) was prepared by dissolving lyophilized peptide in 5 % 
formic acid and was stored at -80 ºC. Stock solutions (2 mM) of Aβ1-42 and Ac-amylin 
8-37 in DMSO were prepared as follows. Peptide was dissolved (1 mg/mL) in 
hexafluoro-2-propanol (HFIP), placed in a bath sonicator for 5 min, and incubated at 
room temperature for 2 hours. Then, HFIP was evaporated by a flow of N2, and dry 
peptide was dissolved in DMSO and stored at -80 ºC. A 0.3 mM stock solution of BSA 
(Sigma-Aldrich) was prepared in PBS buffer (10 mM NaH2PO4, 150 mM NaCl and pH 
7). ThT was purchased from Sigma-Aldrich, and a 650 µM stock solution was prepared 
in PBS buffer. 
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Synthesis and instrumentation for products characterization 
Synthetic procedures, characterization and 1H-NMR and 13C-NMR spectra are reported 
in the Electronic Supplementary Material (ESM). Stock solutions (4 mM) in DMSO 
were prepared for the studied compounds: 3-(4-Oxo-5,6,7,8-tetrahydro-4H-
benzo[4,5]thieno[2,3-d][1,3]oxazin-2-yl)-N-(pyren-1-ylmethyl)propanamide (compound 
1A), 4-(4-Oxo-5,6,7,8-tetrahydro-4H-benzo[4,5]thieno[2,3-d][1,3]oxazin-2-yl)-N-
(pyren-1-ylmethyl)butanamide (compound 1B), 2-Methyl-4-oxo-N-(pyren-1-ylmethyl)-
5,6,7,8-tetrahydro-4H-benzo[4,5]thieno[2,3-d][1,3]oxazine-7-carboxamide (compound 
1C) and N-Acetyl-2-(2-methyl-4-oxo-5,6,7,8-tetrahydro-4H-benzo[4,5]thieno[2,3-
d][1,3]oxazin-7-yl)-N-(pyren-1-ylmethyl)acetamide (compound 1D). Melting points 
were determined in open glass capillaries on a Gallenkamp apparatus. Infrared spectra 
were registered on a Fourier Transform-Infrared spectrometer (Nicolet Avatar 360 FT-
IR). NMR spectra were recorded on a Bruker AV400 spectrometer (400 MHz for 1H-
NMR and 100 MHz for 13C-NMR or APT) or a Bruker AV300 spectrometer (300 MHz 
for 1H-NMR and 75 MHz for 13C-NMR or APT) in the deuterated solvents stated 
(ESM). 1H and 13C chemical shifts were referenced to internal solvent resonances and 
reported relative to TMS. High-resolution electrospray (ESI+) mass spectra were 
registered on a Bruker Daltonics MICROTOF-Q spectrometer using ultra-diluted 
solutions of the chemical compounds in methanol. 
 
Sample preparation for aggregation assays (Turbidimetry, DLS and TEM) 
Samples were prepared from stock solutions of peptide (Aβ17-40) and synthesized 
compounds. Before use, the Aβ17-40 stock solution was filtered for 4 minutes at 4 ºC 
using Ultrafree®-MC filter devices (PVDF 0.22 µM pore size membrane) at 12000 rcf. 
Then, 50 µM Aβ17-40 was mixed with 100 µM compound in PBS buffer and the pH was 
adjusted to 7-8. All final solutions (including controls) contained 2.5 % DMSO. 
 
Turbidimetry assay 
The samples (500 µL) were incubated at room temperature with gentle shaking, and 
aggregation kinetics were followed by recording the absorbance at 650 nm, every 30 
minutes over 8 h, in a Varian Cary 100 Bio spectrophotometer. Quartz cuvettes (Hellma 
119F-QS with 10 mm light path) were used for this purpose. 
 
Dynamic Light Scattering  
The samples (100 µL) were incubated at room temperature with gentle shaking. 
Autocorrelation curves (correlograms) were registered at 25 ºC for 48 hours in a 
DynaPro NanoStar cuvette-based DLS instrument, using Eppendorf UVette plastic 
cuvettes. This system uses a GaAs laser operating at a nominal wavelength of 658 nm, 
and a DLS detector operating at 90 degrees. 20 acquisitions (2 s acquisition time) were 
averaged for each measurement. 
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Transmission Electron Microscopy 
Samples (100 µL) were incubated at 37 ºC for 24 h without shaking. Then, 20 µL-drops 
were placed on carbon support film on a copper 400 mesh grid and negatively stained 
with a 2% uranyl acetate solution for 1 min. Excess stain was removed and samples 
were washed with deionized Milli-Q water and dried at room temperature. TEM images 
were collected at 60 kV under a JEOL JEM 1010 transmission electron microscope 
equipped with a Gatan Bioscan digital camera. 
 
Cytotoxicity assay 
HeLa cells (ATCC CRM-CCL-2), cultured in Dulbecco’s Modified Eagles Medium 
(DMEM) supplemented with penicillin-streptomycin (100 U/mL and 100 µg/mL, 
respectively) and 10% fetal bovine serum (all reagents from PAN-Biotech), were 
aliquoted in 96-well plates (100 µL per well at 3 x 105 cell/mL) and incubated for 24 
hours (37 ºC and 5% CO2) in the absence or presence of compound (at concentrations 
ranging from 0.5 to 200 µM). All wells contained 1% DMSO. After incubation, cell 
media was carefully removed and each well was refilled with 50 µL of a XTT/electron-
coupling agent 500:1 mixture (Cell Proliferation Kit II, Roche). After 4h of incubation, 
optical density was measured at 450 nm (reference wavelength: 650 nm) in a Synergy 
HT spectrophotometer plate reader (100 % viability was considered for controls without 
compound). Half-maximal cytotoxic concentration (CC50) was calculated for 
Compound 1B, by fitting the viability at each concentration to a dose-response curve 
with variable Hill slope (Hill1 implemented in Origin Pro 8 software). 
 
Preparation of fibrils of amyloidogenic peptides for fluorescence microscopy 
assays 
For Aβ1-42 fibrils formation, Aβ1-42 50 µM solutions were prepared in PBS buffer from 
peptide stock solutions, and were incubated at 37 ºC for 24 hours without shaking. The 
same was done with Ac-amylin 8-37. On the other hand, α-PSM1 and α-PSM4 amyloid 
fibrils (200 µM in Milli-Q water) were obtained as described [23].  
 
Detection of amyloid fibrils by fluorescence microscopy 
50 µM amyloid fibrils (obtained as described above) were mixed with 100 µM 
compound (from compound stock solution) in PBS buffer. All final samples (including 
controls) contained 5 % DMSO. Samples (100 µL) were incubated at 37 ºC for 24 h 
without shaking and then centrifuged at 12000 rcf for 15 min at 20 ºC. Supernatants 
were removed and pellets resuspended in 10 µL PBS. A 2-µL drop of each resuspended 
sample was placed on a clear glass microscope slide (25 mm x 75 mm) and covered 
with a 10 mm diameter coverslip. For observation in the fluorescence microscope, a 
DAPI filter (excitation: 360/40 nm; emission: 470/40 nm) was used in a Leica DMI 
6000B multidimensional microscopy system with a 20x microscope objective, 100% 
fluorescence intensity manager (FIM) and 100-ms exposure time. For ThT staining, a 
CFP filter (excitation: 436/20 nm, emission: 480/40 nm) was used instead. For each 
drop, images in 9 chosen-randomly positions were acquired to determine an average 
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value of the pixel intensity and the percentage of fluorescently marked area. These 
parameters were calculated with the Fiji (ImageJ) software applying an Auto-Threshold 
method (Moments) for 8-bit images. 
 
Biofilm formation, staining and observation by fluorescence microscopy 
For biofilm formation, cells (S. aureus SH1000 strain) were grown in PNG (3.3 g/L 
peptone, 2.6 g/L NaCl, 3.3 g/L glucose) or TSBg (0.6 g/L tryptic soy broth, 1.5 g/L 
glucose) culture media at 37 ºC for 24 hours on glass microscope coverslips placed in 
polystyrene cell culture plates. After incubation, biofilms were fixed with 
paraformaldehyde 3% and coverslips were placed over an 80 µL-drop of compound 1D 
(100 µM in H2Omq, 1% DMSO) and incubated at room temperature for 24 hours in a 
humidity chamber. Before observation, biofilms were washed (coverslips were 
immersed in H2Omq three consecutive times) to remove the excess of compound 1D. For 
observation in the fluorescence microscope, a DAPI filter (excitation: 360/40 nm; 
emission: 470/40 nm) was used in a Leica DM4000 B system with a 100x microscope 
objective, 100% fluorescence intensity manager (FIM) and 40-ms exposure time.  
 
Absorption and emission spectra of compounds 1A-D 
Absorption and emission spectra were measured for compounds 1A, 1B, 1C and 1D (30 
µM in PBS buffer with 5% DMSO) using 10 mm light path quartz cuvettes (Hellma 
119F-QS). For absorption spectra, absorbance was recorded between 250 and 800 nm in 
a Varian Cary 100 Bio spectrophotometer. Emission spectra (λex = 350 nm) were 
recorded between 380 and 670 nm at 20 ºC in a Varian Cary Eclipse fluorescence 
spectrophotometer.  
 
Lifetime and quantum yield measurements 
For lifetime measurements, the following samples were prepared from compound and 
peptide stock solutions: compound 1D (30 µM) in the absence or the presence of Aβ1-42 
fibrils (15 µM) in PBS buffer (final solutions contained 5% DMSO). After 24 hours of 
incubation at 37 ºC (for Aβ1-42/1D sample), nanosecond lifetimes were recorded with a 
Datastation HUB-B with a nanoLED controller and software DAS6. The nanoLED 
employed for lifetime measurements was of 340 nm and the data was collected at 466 
nm. The lifetime data were fitted using the Jobin-Yvon software package and the Origin 
Pro 8 program. Quantum yield of compound 1D (30 µM in PBS 5% DMSO) was 
measured using the Hamamatsu Absolute PL Quantum Yield Measurement System 
C11347-11. 
 
Water solubility prediction for compounds 1A-D 
LogS values at 25 ºC, log(solubility in mol/L), for compounds 1A, 1B, 1C and 1D (-9.6, 
-9.8, -9.2 and -9.7, respectively) were predicted using Solubility Predictor by 
ChemAxon. 
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RESULTS AND DISCUSSION 
 
Design of labeled inhibitors 
 
We have chosen Compound 1 (Chart 1) as the scaffold for the design and synthesis of 
Aβ fluorescent markers because it is the more water soluble [17] and less cytotoxic of 
the amyloid aggregation inhibitors previously described [16]. The fluorescent dye 
pyrene has been selected to label Compound 1 because of its high fluorescence quantum 
yield. 1-pyrenemethylamine has been used as reactant in the coupling reaction because 
it allows a fine control of its chemical reactivity. While the residues of Aβ1-40 that 
interact with Compound 1 have been determined [17], the atoms of Compound 1 that 
are engaged in the interaction are not known. Therefore, we have synthesized 4 
derivatives of Compound 1 (Compounds 1A, 1B, 1C and 1D) having the fluorescent 
dye located in different positions or joined with linkers of different length (Chart 1) 
hoping to retain the amyloid binding properties in at least some of them. As shown in 
Fig. S2 in the ESM, compounds 1A, 1B, 1C and 1D display large Stokes shifts (∆λ > 
100 nm), their absorption and emission spectra having maxima at approximately 355 
nm and 470 nm, in PBS buffer. 
 
Synthesis of fluorescent derivatives of compound 1 
 
Schemes 1 and 2 show the synthetic routes to fluorescent derivatives of Compound 1, 
adapted from different methods found in the literature [24–27]. For synthesis of 
compounds 1A and 1B (Scheme 1), the initial step was the nucleophilic attack of 2-
aminotiophene derivative 2 to the cyclic anhydrides 3 and 4, respectively, to obtain 
compounds 5 and 6, which were subsequently transformed into dicarboxylic acids 7 and 
8 by alkaline hydrolysis. Higher yields were obtained for this saponification when it 
was conducted at 36 ºC than when using reflux. The latter conditions led to the 
formation of byproducts, probably as a result of amide saponification. The cyclization 
reaction with acetic anhydride that leads to the key lactone intermediates 9 and 10 was 
performed at room temperature. When it was carried out using reflux conditions, as 
described in the literature [24], unwanted byproducts 9S and 10S (shown in Fig. S1 in 
the ESM) were formed. Crude products 9 and 10 were used in the next step without 
purification. Compounds 1A and 1B were obtained with moderate yields using DCC 
and HOBT as coupling reagents for the amide bond formation. 
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Scheme 1. Synthesis of compounds 1A and 1B 
 
Compounds 1C and 1D were prepared as shown in Scheme 2. Synthesis of starting 
compound 12 was done with 76 % overall yield following methods found in the 
literature [28, 29]. 2-aminothiophenes 13 and 14 were obtained by Gewald reaction [30] 
between cyclohexanones 11 and 12, respectively, ethyl cyanoacetate and powdered 
sulfur. By saponification of 13 and 14, only one ethyl carboxylate was hydrolyzed for 
all tested conditions leading to compounds 15 and 16. After the acetylation step, the 
pyrene fluorescent dye was attached to 17 and 18 using HOBT and EDC as coupling 
agents. Compounds 19 and 20 were hydrolyzed with the less nucleophilic base lithium 
hydroxide to minimize by-product formation due to amide saponification. Finally, 
cyclization of 21 and 22 with acetic anhydride led to compounds 1C and 1D with good 
yields. In these cyclization conditions, the more accessible amide nitrogen of 22 was 
acetylated as it is observed in compound 1D. 
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Scheme 2. Synthesis of compounds 1C and 1D 
 
Anti-aggregational activity of fluorescent derivatives of Compound 1 
 
In a previous study [16] we tested 11250 compounds from two large commercial 
libraries as inhibitors of the aggregation of Aβ17-40 using a ThT fluorescence-based high 
throughput screening assay, which allowed to identify 35 tentative inhibitors. In order to 
discard false positives arising from fluorescence quenching, a turbidimetry assay was 
subsequently done, and 4 inhibitors were finally selected that were confirmed using 
transmission electron microscopy images. On the other hand, to evaluate initially 
whether the synthesized derivatives of Compound 1 could be used as fluorescent 
markers of Aβ fibrils we have first tested them as aggregation inhibitors. Because the 
emission maximum of the four synthesized compounds in aqueous PBS buffer occurs at 
practically the same wavelength as that of Aβ-bound ThT (see Fig. S2 in the ESM and 
reference 18), the classical ThT aggregation assay couldn´t be used. Instead, 
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turbidimetry, dynamic light scattering and transmission electron microscopy assays 
have been conducted. 
The turbidity assay is easy to perform and offers an initial indication of the inhibitory 
capacity of the compounds, which has to be confirmed afterwards by additional tests. 
The assay is based on the apparent enhancement of absorbance that takes place when 
aggregates or other insoluble particles are formed in a solution. To follow aggregation 
kinetics, the absorbance at 650 nm of Aβ17-40 aqueous samples in presence or absence of 
synthesized compounds 1A, 1B, 1C and 1D was monitored every 30 minutes. As the 
assay is noisy and the level of aggregation attained for the control kinetics run without 
compounds shows large variation (see Fig. 1 below; also Fig. 2 in reference [16]) 
individual experiments should not be averaged. Instead, their statistical significance is 
best assessed by Paired t-tests. The kinetics of turbidity enhancement displayed in Fig. 1 
indicate that the four synthesized fluorescent compounds and parent Compound 1 
significantly slow down the aggregation of the amyloid peptide (p < 0.002 in all cases). 
Therefore, compounds 1A, 1B, 1C and 1D are likely to interact with amyloid fibrils, as 
we expected, for at least some of them, from their design.  
 
 
Fig. 1 Turbidimetric monitorization of Aβ17-40 (50 µM) aggregation kinetics in the 
absence (gray circles) and the presence (black squares) of compounds 1, 1A, 1B, 1C and 
1D (100 µM). Statistic results (t-statistic and p-value) of Paired t-tests are shown for 
individual representative experiments. 
13 
 
 
Dynamic light scattering (DLS) [31] has been used to provide additional evidence of the 
inhibitory effect of the fluorescence derivatives on Aβ aggregation. In DLS 
experiments, Brownian motion of particles suspended in a liquid is measured in terms 
of the translational diffusion coefficient, which is inversely related with their size. 
Correlograms (correlation curves) provide qualitative information about the mean size 
of the particles in suspension: the slower the decay, the larger the particle. Thus, larger 
Aβ insoluble aggregates must delay more the decay of the correlation curves. 
Correlograms of aqueous samples of Aβ17-40 in the presence and absence of Compound 
1 measured at different times of incubation (Fig. 2a) reveal that aggregates size 
increases with incubation time and that, for every incubation time, aggregates size was 
smaller in presence of Compound 1, confirming that Compound 1 reduces amyloid beta 
aggregation. DLS experiments with synthesized compounds 1A, 1B, 1C and 1D 
couldn’t be analyzed in the same way because of their low solubility in water due to the 
pyrene moiety (computationally predicted logS values are around -9.6, see Materials 
and Methods,). In fact, Fig. 2b shows that, at zero incubation time, the particles in 
suspension resulting from precipitation of the synthesized fluorescent compounds in 
PBS buffer (colored curves) were larger than the initial amyloid aggregates (black 
curve). However, as the aggregation of Aβ progressed, the particle size of all samples 
increased in such a way that, at 48 hours of incubation, aggregates of Aβ17-40 samples in 
the presence of compounds 1A, 1B, 1C and 1D were smaller than those of Aβ17-40 
samples without compound (Figure 2c). Therefore DLS analysis also indicates that 
compounds 1A, 1B, 1C and 1D inhibit the aggregation of Aβ17-40. 
Finally, transmission electron microscopy (TEM) images of Aβ17-40 fibrils were 
acquired to compare the morphology of the amyloid aggregates formed in the presence 
or absence of fluorescent compounds 1A, 1B, 1C and 1D or parent Compound 1 (Fig. 
3). When Aβ17-40 was incubated alone, TEM images taken after 24 hours of incubation 
at 37 ºC showed a meshwork of aggregates so dense that isolated fibrils could not be 
observed. In contrast, in amyloid peptide samples incubated in the presence of these 
compounds, the fibrillary net was more clear and isolated fibrils could be detected that 
were similar to those formed in presence of the inhibitory parent Compound 1. Thus, 
turbidimetry, DLS and TEM assays indicate that the four fluorescent derivatives of 
Compound 1 interact with Aβ aggregates and give grounds to the possibility of using 
1A, 1B, 1C and 1D as Aβ fibrils fluorescent stains. 
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Fig. 2 Dynamic light scattering monitorization of the aggregation kinetics of Aβ17-40 (50 
µM) in the presence and absence of the studied compounds (100 µM). a) Truncated 
correlograms measured at different incubation times (see the legend) of Aβ17-40 samples 
in the absence (solid line) and the presence (dashed line) of Compound 1. b) Truncated 
correlograms measured at zero incubation time of Aβ17-40 samples in the absence and 
the presence of compounds 1A, 1B, 1C and 1D (see the legend) revealing the presence 
of compound aggregates due to poor solubility. c) Truncated correlograms measured at 
48 h incubation time of Aβ17-40 samples in the absence and the presence of compounds 
1A, 1B, 1C and 1D (see the legend). 
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Fig. 3 Morphology of Aβ17-40 insoluble aggregates. Transmission electron microscopy 
images (negative stain) of Aβ17-40 (50 µM) samples, with or without aggregation 
inhibitors (100 µM), acquired after incubation at 37 ºC for 24 h. Scale bar = 0.2 µm. 
 
Cytotoxicity of the compounds 
 
Because compounds 1A, 1B, 1C and 1D reduced Aβ17-40 fibrillar growth, we have 
evaluated their cytotoxicity to obtain a preliminary indication of their potential as 
labeling agents in living tissues. For that purpose, a cytotoxicity assay of the four 
synthesized compounds was performed by measuring HeLa cells viability after 24 hours 
incubation in presence of 1A, 1B, 1C or 1D. The toxicity curves used to calculate half-
maximal cytotoxic concentrations (CC50) of the synthesized fluorescent compounds are 
represented in Fig. 4. Due to the low solubility of the tested compounds, 200 µM was 
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the highest concentration evaluated. The most toxic compound was 1B (CC50 = 112 
µM). The three other compounds, 1A, 1C and 1D, with CC50> 200 µM, are less toxic 
for HeLa cells than the unlabeled, parent Compound 1 (CC50 = 184 µM) [16]. 
 
 
 
 
Fig. 4 Cell viability of HeLa cells (3 x 105 cell/mL) treated with different concentrations 
of compounds 1A, 1B, 1C and 1D. Mean ± SD (n = 3) is shown for every compound 
concentration. CC50 indicates the compound concentration that cause death to 50 % of 
cells (50 % viability) according to the fit of the experimental data. 
 
Use of compound 1D for the detection of Aβ1-42 fibrils by fluorescence microscopy  
 
Since compounds 1A, 1B, 1C and 1D have appropriate fluorescent properties with high 
Stokes shifts and they seem to interact with Aβ aggregates, fluorescence microscopy 
can be used to detect amyloid fibrils resulting from Aβ aggregation. For that purpose, 
aqueous samples of compound (100 µM) and Aβ1-42 fibrils (50 µM) were incubated for 
24 h at 37 ºC, and insoluble fluorescently labeled amyloid aggregates were analyzed by 
fluorescence microscopy. In view of the spectroscopic properties of the compounds, a 
DAPI filter (ex: 360/40 nm, em: 470/40 nm) was used. Due to the poor solubility of the 
synthesized fluorescent probes, a background fluorescent signal was observed when 
they were incubated without peptide. Compound 1D gave the lowest background signal, 
which agrees with its greater solubility as detected in DLS experiments (Fig. 2b) and 
with other visual observations (not shown), so it was selected for this study. To evaluate 
the ability of compound 1D as fluorescent marker of Aβ1-42 fibrils, we first verified that 
Aβ1-42/1D samples generated a higher fluorescent signal than the background observed 
for compound samples without peptide. A quantitative comparison was made by 
calculating the average percentage of fluorescently labeled area in microscope images 
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of Aβ1-42/1D and compound 1D alone samples (see representative images in Figs. 5a 
and 5b). The percentages of fluorescently marked area (means of three duplicated 
experiments ±SD) were 6.55 ±1.13 and 0.96 ±0.26, for Aβ1-42/1D samples and 
compound 1D alone, respectively. Those percentages are statistically different with a 
confidence level of p < 0.001. That the fluorescence signal observed in the Aβ1-42/1D 
samples was due to the interaction between peptide and probe was indicated by the 
signal concentration dependence: fluorescence values decrease both with decreasing 
concentrations of 1D at constant Aβ1-42 concentration (Fig. 6a) and with decreasing 
peptide concentration at constant concentration of 1D (Fig. 6b). On the other hand, to 
demonstrate that the molecular fragment of 1D responsible for the interaction with Aβ1-
42 (and for the resulting fluorescent identification) is the one derived from parent 
compound 1 and not the pyrene fluorescent label, the fluorescence intensity of Aβ1-42 
fibrils incubated in presence of 1D or pyrene was compared. To do that, the average 
pixel intensity of the microscope images, related with the sensitivity in Aβ staining of 
the two different compounds, was determined. As expected from the high 
hydrophobicity of the pyrene moiety, Aβ fibrils were fluorescently marked but the 
obtained intensity observed in presence of 1D was 3.2 times higher (Fig. 7). That 
Compound 1D interacts with Aβ1-42 fibrils through its inhibitor moiety, as per design, is 
also indicated by the fact that its fluorescence lifetime hardly changes upon binding: 41 
ns in PBS 5% DMSO versus 39 ns when bound to the fibrils. It is also suggested by the 
fact that the emission maximum does not change either (not shown). 
 
Selectivity and sensitivity of compound 1D for the detection of amyloid fibrils 
 
To evaluate the selectivity of compound 1D as Aβ fibrils fluorescent stain, α-synuclein 
and amylin amyloid fibrils, as well as bovine serum albumin (BSA), were incubated 
with compound 1D. BSA was chosen as an example of soluble, non amyloidogenic 
protein because it contains hydrophobic pockets that could interact with compound 1D. 
The signal value (percentage of fluorescently marked area) of BSA/1D sample before 
24 hours of incubation was not significantly different from background signal of 1D 
sample (Fig. 8a). However, microscope images of 1D and of BSA/1D samples were 
qualitatively different suggesting that soluble BSA interacts with compound 1D in some 
way and makes it precipitate as smaller and more homogeneous particles (see 
representative images in Fig. 5b and 5e). Something similar occurred with α-syn/1D 24 
h-incubated sample. Although no amyloidogenic fibrils of this protein are formed in 24 
h, compound 1D appears to interact with soluble α-syn as with BSA, giving rise to a 
more homogeneous background (not shown). Importantly, the low reproducibility in α-
syn aggregation results in a low reproducibility in the staining of preformed α-syn 
fibrils, which, when a good aggregation is achieved, are stained by 1D similarly to Aβ. 
On the other hand, amylin fibrils were also marked with compound 1D in the same 
manner as Aβ (Fig. 8b). Therefore, compound 1D is not specific of Aβ aggregates but 
can label a variety of amyloid fibrils. The intensity of Aβ1-42 and amylin fibrils stained 
with 1D has been compared to that of fibrils stained with ThT. To record the emission 
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fluorescence of ThT samples a CFP filter (ex: 436/20 nm, em: 480/40 nm) was used, 
whose excitation and emission wavelengths fit with ThT spectroscopic properties. 
Results presented in Fig. 7 show that compound 1D stained Aβ1-42 and amylin insoluble 
fibrils almost as efficiently as ThT, generating, in our staining conditions, fluorescent 
signals 0.6 and 0.7 times those of ThT, respectively. To sum up, compound 1D, a 
pyrene labeled inhibitor of Aβ1-42 aggregation, can be used to monitor by fluorescence 
microscopy the presence of Aβ1-42 fibrils as well as those of α-synuclein and amylin. On 
the other hand, compound 1D can be efficiently excited in the UV region and displays a 
large Stokes shift: ∆λ = 116 nm in our microscope filter conditions, and ∆λ = 186 nm if 
excitation is conducted at 280 nm (Fig. 9). It thus provides an alternative spectroscopic 
window for the detection of amyloid fibrils and facilitates minimizing crosstalk between 
the excitation source and the fluorescent emission [32]. In addition, compound 1D is 
photostable, its fluorescence is insensitive to changes in pH (see Fig. S3 in the ESM) 
showing a quantum yield of 0.23 in PBS 5% DMSO, and its low cytotoxicity allows its 
use for in vivo staining. Table 1 compares properties of compound 1D with those of 
commonly employed amyloid stains Thioflavin T and Congo Red. 
 
Table 1. Comparison of compound 1D, Thioflavin T and Congo Red amyloid stain 
properties.  
 Compound 1D Thioflavin T Congo Red 
Amyloid detection method Fluorescence Fluorescence Absorption/Dichroism 
Absorption maximum 350 nm 445 nma 490 nmb 
Emission maximum 466 nm 485 nma N/A 
Stokes shift 116 nm 40 nm N/A 
Aβ selectivityc No No No 
Fluorescence intensity 
(relative to Aβ/1D interaction) 1.0 1.7 N/A 
Useful pH range 2.0 – 10.0d 3.0 – 8.5e > 5.0b 
Water solubility (logS) -9.7f -1.8g -1.4h 
N/A value not available (not related with the detection method). 
aReference [33]. 
bReference [34]. 
cSpecificity for Aβ staining in relation to other amyloid fibrils. 
dAssayed range (Fig. S3). 
eReference [35]. 
fComputationally predicted by ChemAxon’s Solubility Predictor. 
gObtained from Merck Millipore product information. 
hReference [36]. 
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Fig. 5 Fluorescence microscope images of pellets obtained after 24 h of incubation at 37 
ºC for the following aqueous (PBS) samples. a) Aβ1-42 fibrils (50 µM) and compound 
1D (100 µM). b) Compound 1D (100 µM) alone. c) Aβ1-42 fibrils (50 µM) and 
fluorescent dye (1-Pyrenemethylamine hydrochloride, 100 µM). d) Aβ1-42 fibrils (50 
µM) and ThT (100µM). e) BSA (50 µM) and compound 1D (100 µM). f) α-syn fibrils 
(50 µM) and compound 1D (100 µM). Scale bar = 100 µm. 
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Fig. 6 Quantitative analysis and statistical comparison of the percentage of fluorescent 
area in the microscope images acquired for the indicated samples (for their pellets) after 
incubation at 37 ºC for 24 h. a) Compound 1D (different concentrations) in the presence 
(black column) and absence (gray column) of Aβ1-42  fibrils (50 µM). b) Compound 1D 
(100 µM) in the presence (black column) and absence (gray column) of Aβ1-42 fibrils 
(different concentrations). Statistical differences were evaluated by Student’s t-test (*** 
means p < 0.001, ** means p < 0.01 and n.s. means non-significant differences). Error 
bars represent SD of the measurement. 
 
 
 
 
 
 
Fig. 7 Quantitative analysis and statistical comparison of the pixel intensity in the 
microscope images acquired for the indicated samples (for their pellets) after incubation 
at 37 ºC for 24 h: Aβ1-42 fibrils (50 µM) in the presence of 100 µM 1D (black column), 
100 µM pyrene fluorescent dye (light gray column) or 100 µM ThT (gray column). 
Amylin fibrils (50 µM) in the presence of 100 µM 1D (dark gray column) or 100 µM 
ThT (white column). Statistical differences were evaluated by Student’s t-test (*** 
means p < 0.001). Error bars represent SD of the measurement. 
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Fig. 8 Quantitative analysis and statistical comparison of the percentage of fluorescent 
area in the microscope images acquired for the indicated samples (for their pellets) after 
incubation at 37 ºC for 24 h. a) Compound 1D (100 µM) in the absence (light gray 
column) and presence of 50 µM Aβ1-42 fibrils (black column) or 50 µM soluble BSA 
(dark gray column). b) Compound 1D (100 µM) in the presence of fibrils (50 µM) of 
Aβ1-42 (black column), α-syn (dark gray column), amylin (light gray column) and α-
PSM4 (pale gray column). Statistical differences were evaluated by Student’s t-test (*** 
means p < 0.001 and n.s. means non-significant differences). Error bars represent SD of 
the measurement. 
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Fig. 9 Stokes shifts of compound 1D. Absorption and emission (excitation wavelength: 
350 nm, blue solid line, and 280 nm, blue dashed line) spectra obtained in PBS buffer 
(30 µM, 5% DMSO) 
 
Use of compound 1D to detect amyloid fibrils of α-PSM4 by fluorescence 
microscopy 
 
In Staphylococcus aureus, phenol soluble modulins (PSMs) peptides are known to be 
important constituents of the extracellular biofilm matrix that provide the bacteria with 
resistance to chemicals and host immune response. From all PSMs studied (α-PSM1-4), 
only α-PSM1 and α-PSM4 showed amyloidogenic properties, with α-PSM4 having the 
greater ability to form ordered amyloid fibrils [23]. 
We have evaluated the ability of fluorescent compound 1D to stain α-PSM1 and α-
PSM4 fibrils by fluorescence microscopy in the same manner as for the other studied 
peptides. α-PSM4 fibrils were stained by 1D similarly to Aβ and the other 
amyloidogenic fibrils (Fig. 8b). However, compound 1D showed a lower sensitivity for 
α-PSM1 fibrillar solution, generating a signal 2.9 times less intense than for α-PSM4 
fluorescently stained fibrils (Fig. 10), which correlates well with the much weaker 
amyloidogenic properties of α-PSM1 peptide, as previously described [23]. 
Therefore, compound 1D could be a useful tool to analyze the amyloid nature of PSMs 
fibrils. 
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Fig. 10 Quantitative analysis and statistical comparison of the pixel intensity in the 
microscope images acquired for the following samples (for their pellets) after 
incubation at 37 ºC for 24 h: α-PSM4 fibrils (50 µM) in the presence of 100 µM 1D 
(black column) and α-PSM1 fibrils (50 µM) in the presence of 100 µM 1D (gray 
column). Statistical differences were evaluated by Student’s t-test (*** means p < 
0.001). Error bars represent SD of the measurement. 
 
Use of compound 1D to analyze the amyloid nature of Staphylococcus aureus 
extracellular biofilm matrix 
 
Biofilm formation is universal for all bacteria but the nature of the biofilm matrix 
composition varies by strain, physiological state and nutrient availability. S. aureus 
SH1000 biofilms grown in peptone-NaCl-glucose (PNG) media develop an extracellular 
matrix composed of amyloid fibrils of phenol soluble modulins [22]. However, when 
grown in tryptic soy broth supplemented with glucose (TSBg), the biofilm matrix lacks 
amyloid and becomes less stable. 
We have tested compound 1D as fluorescent stain for amyloid-like extracellular matrix 
using S. aureus SH1000 biofilms grown in PNG media and subsequently exposed to an 
aqueous solution of the studied compound. Fluorescence microscopy images showed a 
clear interaction between compound 1D and the amyloid extracellular components 
(PSMs fibrils) of the biofilm matrix (Fig. 11a). Interestingly, this interaction was not 
observed for S. aureus SH1000 biofilms grown in TSBg media (Fig. 11b), indicating 
that compound 1D is useful to stain PSM-derived biofilm matrix and therefore to 
distinguish between S. aureus biofilms that contain or lack amyloid fibrils.  
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Fig. 11 Microscope images (left: bright field, right: DAPI fluorescent filter) of S. aureus 
SH1000 biofilms grown in a) PNG culture media (zoomed inset) or b) TSBg culture 
media and incubated with 100 µM 1D. Scale bar = 10 µm. 
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CONCLUSIONS 
 
Synthetic procedures have been developed to attach pyrene, a high quantum yield 
fluorescent dye, to different positions of Compound 1, a previously reported inhibitor of 
Aβ peptide aggregation. The resulting fluorescent compounds 1A, 1B, 1C and 1D have 
been tested in terms of sensitivity and selectivity for the fluorescent staining of 
insoluble amyloid fibrils. Turbidimetry, DLS and TEM assays indicate that the four 
synthesized compounds interact with Aβ17-40 aggregates in a similar way as the parent 
Compound 1. The more water soluble compound 1D was selected to evaluate its ability 
as Aβ1-42-fibrils fluorescent marker. Fluorescence microscopy monitoring reveals that 
compound 1D can be used to stain Aβ1-42 fibrils as well as those formed by other 
amyloidogenic peptides such as amylin or α-synuclein, offering a sensitivity close to 
that of ThT staining. Compound 1D displays a conveniently large Stokes shift, it is 
photostable, shows a pH-independent fluorescence quantum yield and it is not 
cytotoxic. Furthermore, compound 1D can stain the amyloidogenic components (PSMs) 
of the Staphylococcus aureus biofilm matrix and allows distinguishing by direct 
staining biofilms that contain amyloid fibrils from those lacking them. Because chronic 
biofilm-associated infections caused by Staphylococcus aureus often lead to significant 
increases in morbidity and mortality, a better understanding of the composition of 
staphylococcal biofilm matrix, for which compound 1D constitutes a novel tool, is 
imperative to generate more accurate treatment strategies. 
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ASSOCIATED CONTENT 
 
Electronic Supplementary Material (ESM): Synthetic procedures, characterization, 
1H-NMR spectra and 13C-NMR spectra of all synthesized compounds. Additional 
figures cited in the text (Figures S1 to S3). 
 
ABBREVIATIONS 
 
AD, Alzheimer’s disease; Aβ, amyloid beta; APP, β-amyloid precursor protein; ThT, 
Thioflavin T; PSMs, phenol soluble modulins; DLS, dynamic light scattering; TEM, 
transmission electron microscopy; CC50, half-maximal cytotoxic concentration; BSA, 
bovine serum albumin; α-syn, α-synuclein; DMEM, Dulbecco’s Modified Eagles 
Medium; DAPI, 4',6-Diamidine-2'-phenylindole; GFP, green fluorescent protein; PNG, 
peptone-NaCl-glucose media; TSBg, tryptic soy broth supplemented with glucose; PBS, 
phosphate-buffered saline; DMSO, dimethyl sulfoxide; DCC, N,N'-
Dicyclohexylcarbodiimide; EDC, 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide, 
HOBT, 1-Hydroxybenzotriazole. 
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